RE:RE:liver fibrosis progression via VEGF-A Also just saw this abstract that's just out.
https://link.springer.com/article/10.1007/s13105-020-00777-7
PPAR drugs are another class of anti-NASH drugs. This paper suggests they work by affecting hepatic Stellate cells and down-regulating TGF-beta1 which is over-expressed during NASH. So potentially tesamorelin does what a PPAR drug does plus more, I think that's because GH/IGF-1 upregulates PPAR pathways as well as having other effects. I probably said this before but it's hard not to think of Egrifta as a combo drug treatment all in one molecules because it sits upstream of so many different processes.
jeffm34 wrote: TGF-β1 (transforming growth factor β1) was found to be mainly responsible for the up-regulation of CD147. Bioinformatic and experimental data suggest a functional link between CD147 expression and VEGF-A (vascular endothelial growth factor A)/VEGR-2 (VEGF receptor 2) signalling-mediated angiogenesis in fibrotic liver tissues.
Tesamorelin decreases TGF-B1 which appears to down regulate CD147 which decreases VEGF-A